Clinical observation of hydroprednisone and glutathione in chemotherapy of breast cancer

Chinese Journal of Cancer Prevention and Treatment

Volumn 17, Issue 2, 2010, Pages 131-133

  Gu, Hong Shuai ^a   Li, Jian Yi ^a   Zhang, Wen Hai ^a   Zhang, Yang ^a   Jia, Shi ^a   Fu, Yu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast neoplasms drug therapy; Glutathione; Hydroprednisone

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; GLUTATHIONE; HYDROPREDNISONE; PREDNISONE; TROPISETRON; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW DEPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAM; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOCYTOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

EID: 77953447172     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gonzalez-Angulo A M, Walters R, Broglio K, et al. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer [J], Clin Breast Cancer, 2008, 8(6):516-521.
2. Trudeau M, Charbommeau F, Gelmon K, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer [J]. Lancet Oncol, 2005, 6(11):886-898. (Pubitemid 41614801)
3. Johansson K, Ahlen K, Rinaldi R, et al. Microsomal glutathione transferase 1 in anticancer drug resistance [J]. Carcinogenesis, 2007, 28(2):465-470. (Pubitemid 46321864)
4. Perez-Ruixo J J, Chen W, Zhang S, et al. Exposure-toxicity relationships for tipifarnib in cancer patients [J]. Br J Clin Pharmacol, 2007, 64(2):219-232. (Pubitemid 47063250)
5. Azambuja E, Paesmans M, Beauduin M, et al. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study [J]. J Clin Oncol, 2009, 27(5):720-725.
6. Tsai C F, Hsu Y W, Chen W K, et al. Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells due to electrolyzed-reduced water and glutathione [J]. Biosci Biotechnol Biochem, 2009, 73(2):280-287.
7. Stocco G, Martelossi S, Barabino A, el al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease [J]. Inflamm Bowel Dis, 2007,13(1):57-64.
8. Rao X P, Zhu L Q, Lian H H. Protective effects of glutamine on the intestinal mucosal barrier in young rabbits under hemorrhagic shock [J]. Zhongguo Dang Dai Er Ke Za Zhi, 2006, 8(1):66-70. (Pubitemid 43299393)
9. Mossallam G I, Abdel Hamid T M, Samra M A. Glutathione Stransferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy [J]. J Egypt Natl Canc Inst, 2006, 18(3):264-273.
10. Pereira-Filho G, Ferreira C, Schwengber A, et al. Role of N-acetylcysteine on fibrosis and oxidative stress in cirrhotic rats [J]. Arq Gastroenterol, 2008, 45(2):156-162.
11. Zhong S, Huang M, Yang X, et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus [J]. Br J Clin Pharmacol, 2006, 62(4):457-472. (Pubitemid 44401529)
12. Abils J, Moreno-Torres R, Moratalla G, et al. Effects of supply with glutamine on antioxidant system and lipid peroxidation in patients with parenteral nutrition [J]. Nutr Hosp, 2008, 23(4):332-339. (Pubitemid 352030204)
13. Townsend D M, Tew K D, He L, et al. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity [J]. Biomed Pharmacother, 2009, 63(2):79-85.
14. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial [J]. Lancet Oncol, 2009, 10(2):115-124.
15. Schmoll H J, Aapro M S, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day on dansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment [J]. Ann Oncol, 2006, 17(6):1000-1006. (Pubitemid 43778994)
16. Herrington J D, Jaskiewicz A D, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induce nausea and vomiting [J]. Cancer, 2008, 112(9):2080-2087. (Pubitemid 351574085)
17. Narang V S, Fraga C, Kumar N, et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier [J]. Am J Physiol Cell Physiol, 2008, 295(2):440-450. (Pubitemid 352755780)
18. Lindley C, Goodin S, McCune J, et al. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone [J]. Am J Clin Oncol, 2005, 28(3):270-276. (Pubitemid 40800479)
19. Fujii Y, Nakayama M. Reducetion of postoperative nausea and vomiting and analgesic requirement with dexamethasone in women undergoing general anesthesis for mastectomy [J]. Breast J, 2007,13(6):564-567. (Pubitemid 350045696)
20. Wang H, Wang Y, Rayburn E R, et al. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics [J]. Int J Oncol, 2007, 30(4):947-953.
21. Srivastava A S, Kaushal S, Mishra R, et al. Dexamethasone facilitates erythropoiesis in murine embryonic stem cells differentiating into hematopoietic cells in vitro [J]. Biochem Biophys Res Commun, 2006, 346(2):508-516. (Pubitemid 43902713)